Approvals, Surges, And Variants

More incremental vaccine news greeted markets Wednesday as AstraZeneca and the University of Oxford’s COVID-19 shot won approval in the UK, marking the first regulatory clearance for the injection. Although Astra's shot presents fewer logistical challenges than the more effective Pfizer-BioNTech vaccine, there are still questions about its efficacy stemming from somewhat confusing trial data. Approval in the US and the EU isn't imminent, although German officials said the process could procee

Get the best daily market and macroeconomic commentary anywhere for less than $7 per month.

Subscribe today

Already have an account? log in

Speak your mind

This site uses Akismet to reduce spam. Learn how your comment data is processed.

3 thoughts on “Approvals, Surges, And Variants

    1. Yeah the logistics issue alone is a true nightmare especially when so many are out of work or have been avoiding healthcare in general due to exorbitant costs for decades. There is no real functional delivery system capable of managing a two injection immunization across the entire population in a matter of months. I read that once delivered the Pfizer vaccine lasts about 5 days at a hospital in cold storage. The dry ice required for shipping is itself becoming a scarce commodity.

NEWSROOM crewneck & prints